Drugs & Pharmaceuticals M&A » By The Online Investor Staff, updated Sat., Apr. 20, 3:09 AM
Recent mergers and acquisitions in the Drugs & Pharmaceuticals M&A category.
Slide #81. Amgen — Onyx Pharmaceuticals
Acquirer: |
Amgen (AMGN) |
Acquiree: |
Onyx Pharmaceuticals (ONXX) |
Details: |
Amgen (NASDAQ:AMGN) and Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) today announced that their Boards of Directors have unanimously approved a transaction under which Amgen will acquire all of the outstanding shares of Onyx for $125 per share in cash. The purchase price is $10.4 billion, or $9.7 billion net of estimated Onyx cash. |
Amgen is a biotechnology company that focuses on discovering, developing, manufacturing and delivering human therapeutics. Co.'s principal products are Enbrel® (etanercept), Prolia® (denosumab), Otezla® (apremilast), XGEVA® (denosumab), Neulasta® (pegfilgrastim), Aranesp® (darbepoetin alfa), Repatha® (evolocumab), KYPROLIS® (carfilzomib) and Nplate® (romiplostim). Co. also markets a number of other products, including among other, MVASI® (bevacizumab-awwb), Vectibix® (panitumumab), KANJINTI® (trastuzumab-anns), EVENITY® (romosozumab-aqqg), EPOGEN® (epoetin alfa), BLINCYTO® (blinatumomab), AMGEVITA (adalimumab), Aimovig® (erenumab-aooe), Parsabiv® (etelcalcetide) and NEUPOGEN® (filgrastim).
Amgen SEC Filing Email Alerts Service
Open the AMGN Page at The Online Investor »
Amgen is a biotechnology company that focuses on discovering, developing, manufacturing and delivering human therapeutics. Co.'s principal products are Enbrel® (etanercept), Prolia® (denosumab), Otezla® (apremilast), XGEVA® (denosumab), Neulasta® (pegfilgrastim), Aranesp® (darbepoetin alfa), Repatha® (evolocumab), KYPROLIS® (carfilzomib) and Nplate® (romiplostim). Co. also markets a number of other products, including among other, MVASI® (bevacizumab-awwb), Vectibix® (panitumumab), KANJINTI® (trastuzumab-anns), EVENITY® (romosozumab-aqqg), EPOGEN® (epoetin alfa), BLINCYTO® (blinatumomab), AMGEVITA (adalimumab), Aimovig® (erenumab-aooe), Parsabiv® (etelcalcetide) and NEUPOGEN® (filgrastim).
Amgen SEC Filing Email Alerts Service
Open the ONXX Page at The Online Investor »
Company Name: |
Amgen Inc |
Stock buyback: |
AMGN buyback |
Website: |
www.amgen.com |
Sector: |
Biotechnology |
Number of ETFs Holding AMGN: |
133 |
Total Market Value Held by ETFs: |
$22.26B |
Total Market Capitalization: |
$142.36B |
% of Market Cap. Held by ETFs: |
15.64% |
|